高级检索
当前位置: 首页 > 详情页

Ad.mda-7 (IL-24) Selectively Induces Apoptosis in Hepatocellular Carcinoma Cell Lines, Suppresses Metastasis, and Enhances the Effect of Doxorubicin on Xenograft Tumors

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Tongji Univ, Sch Med, Shanghai E Hosp, Dept Gen Surg, Shanghai 200120, Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Biliary & Pancreat Surg,Wuhan 430074,Peoples R China [3]Wuhan Univ, Coll Med, Zhongnan Hosp, Dept Oncol, Wuhan 430072, Peoples R China
出处:
ISSN:

关键词: Hepatocellular carcinoma (HCC) MDA-7/IL-24 Apoptosis Growth arrest Gene therapy Signal transducer and activator of transcription 3 (STAT3) Doxorubicin (ADM) Metastasis Antiangiogenesis

摘要:
Overexpression of the melanoma differentiation associated gene-7 (MDA-7)/IL-24 in vitro generally results in the growth suppression and induction of apoptosis of diverse human tumor cells. In this study, we investigated the effects of overexpression of the MDA-7/IL-24 gene in human hepatocellular carcinoma (HCC) cells in vitro and in vivo. Adenovirus-mediated overexpression of MDA-7 facilitated the MDA-7/IL-24-induced apoptosis and G(2)/M arrest in HCC cells, but not in the normal liver cell line L02, and the effect was independent of the p53 status. Inhibition of metastasis and angiogenesis was correlated with decreasing expression of STAT3, P-STAT3, MMP-2, VEGF, and TGF-beta genes, regulated by STAT3 in MHCCLM6 cells. We also showed that Ad.mda-7 combined with doxorubicin (ADM) had significantly enhanced antitumor and antimetastatic effects in vivo, accompanied by the downregulation of VEGF, MMP-2, and TGF-beta genes and the upregulation of E-cadherin genes. These data suggested that MDA-74L-24 induces its selective antitumor properties in HCC cells by promoting apoptosis independent of p53 status, inhibiting subcutaneous tumor growth and metastasis, and increasing the effect of chemotherapeutic agents. MDA-71IL-24 represents a new class of cancer suppressor genes that may be useful in the targeted therapy of HCC.

基金:

基金编号: 30872510 2006AA301B52-4 2008CDB127

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2009]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2008]版:
Q4 ONCOLOGY
最新[2023]版:
Q3 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2008版] 出版当年五年平均 出版前一年[2007版] 出版后一年[2009版]

第一作者:
第一作者单位: [1]Tongji Univ, Sch Med, Shanghai E Hosp, Dept Gen Surg, Shanghai 200120, Peoples R China [*1]Tongji Univ, E Hosp Affiliated, Dept Gen Surg, 150 Jimo Rd, Shanghai 200120, Peoples R China
通讯作者:
通讯机构: [1]Tongji Univ, Sch Med, Shanghai E Hosp, Dept Gen Surg, Shanghai 200120, Peoples R China [*1]Tongji Univ, E Hosp Affiliated, Dept Gen Surg, 150 Jimo Rd, Shanghai 200120, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:428 今日访问量:1 总访问量:411 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)